HBIO vs. INOD, GEOS, BZUN, TRVG, KLTR, REKR, RELL, RMBL, AEYE, and UEIC
Should you be buying Harvard Bioscience stock or one of its competitors? The main competitors of Harvard Bioscience include Innodata (INOD), Geospace Technologies (GEOS), Baozun (BZUN), trivago (TRVG), Kaltura (KLTR), Rekor Systems (REKR), Richardson Electronics (RELL), RumbleOn (RMBL), AudioEye (AEYE), and Universal Electronics (UEIC). These companies are all part of the "computer and technology" sector.
Harvard Bioscience (NASDAQ:HBIO) and Innodata (NASDAQ:INOD) are both small-cap computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, community ranking, risk, profitability, media sentiment and institutional ownership.
80.9% of Harvard Bioscience shares are owned by institutional investors. Comparatively, 30.8% of Innodata shares are owned by institutional investors. 9.0% of Harvard Bioscience shares are owned by insiders. Comparatively, 18.2% of Innodata shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, Harvard Bioscience had 29 more articles in the media than Innodata. MarketBeat recorded 31 mentions for Harvard Bioscience and 2 mentions for Innodata. Innodata's average media sentiment score of 0.00 beat Harvard Bioscience's score of -0.23 indicating that Innodata is being referred to more favorably in the news media.
Harvard Bioscience received 258 more outperform votes than Innodata when rated by MarketBeat users. Likewise, 72.16% of users gave Harvard Bioscience an outperform vote while only 49.55% of users gave Innodata an outperform vote.
Harvard Bioscience has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Innodata has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500.
Innodata has lower revenue, but higher earnings than Harvard Bioscience. Innodata is trading at a lower price-to-earnings ratio than Harvard Bioscience, indicating that it is currently the more affordable of the two stocks.
Innodata has a net margin of -1.05% compared to Harvard Bioscience's net margin of -3.04%. Harvard Bioscience's return on equity of 2.75% beat Innodata's return on equity.
Summary
Harvard Bioscience beats Innodata on 8 of the 15 factors compared between the two stocks.
Get Harvard Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for HBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Harvard Bioscience Competitors List
Related Companies and Tools
